Succinate dehydrogenase-deficient tumors: diagnostic advances and clinical implications

Area of Science:

• Oncology
• Genetics
• Biochemistry

Background:

• Germline mutations in SDHD, a succinate dehydrogenase (SDH) gene, were identified in hereditary paraganglioma-pheochromocytoma syndrome patients over a decade ago.
• Subsequent research revealed that all SDH genes are implicated in tumorigenesis.
• SDH gene involvement extends beyond paragangliomas/pheochromocytomas to include other tumor types, such as gastrointestinal stromal tumors.

Purpose of the Study:

• To review the genetics of tumors with SDH deficiencies.
• To explore potential mechanisms driving tumorigenesis in these tumors.
• To describe methods for identifying SDH-deficient tumors using immunohistochemistry.

Main Methods:

• Literature review of genetic studies on SDH-related tumors.
• Analysis of proposed molecular mechanisms in SDH-deficient tumorigenesis.
• Summary of immunohistochemical techniques for tumor identification.

Main Results:

• All four SDH genes (SDHA, SDHB, SDHC, SDHD) are associated with tumor development.
• SDH gene mutations disrupt the mitochondrial respiratory complex II, impacting cellular metabolism.
• Immunohistochemistry can effectively identify tumors lacking SDH protein expression.

Conclusions:

• SDH gene mutations are a significant factor in the development of paragangliomas, pheochromocytomas, and gastrointestinal stromal tumors.
• Understanding SDH genetics and tumorigenesis is crucial for diagnosis and potential therapeutic strategies.
• Immunohistochemistry serves as a valuable diagnostic tool for SDH-deficient tumors.